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Abstract
Background: Human glycosylase IV is involved in GLUT2 transporter regulation in pancreatic β
cells. A KO of this gene along with a high fat diet in a mice model has been associated with the
development of type 2 diabetes (T2D). The aims of this study were to measure and compare the
MGAT4A mRNA levels in white blood cells (WBC) from T2D subjects and healthy subjects (T2NB),
and to measure the half-life of the MGAT4A mRNA.
Results:  We studied a sample of 73 individuals, 40 T2D subjects and 33 T2NB subjects.
Anthropometrical and biochemical profiles were registered. The MGAT4A mRNA levels in WBC
and the transcript half-life in Jurkat T cells were determined by Real-Time PCR. A blood differential
cell counting was made for each individual. Cell counting showed T2D subjects exhibited an
increased number of WBC compared to T2NB subjects (P = 0.0001). Biochemical parameters such
as fasting glucose (P = 0.0001), and triglycerides (P = 0.002) were statistically significant. T2D
subjects had 4.2-fold more MGAT4A transcript compared to T2NB subjects (P = 0.002). The
MGAT4A mRNA had a half-life of 2.04 h in Jurkat T cells.
Conclusion: The results of this work suggest that in T2D subjects, high levels of glucose and
triglycerides are accompanied by an increase on MGAT4A mRNA levels and WBC count; condition
that suggests a pro-inflammatory state due to a chronic metabolic stress.
Background
The human MGAT4A gene encodes a glycosyltransferase
regulating the formation of tri- and multiantennary
branching structures on membrane proteins that require
glycosylation as signal for its exportation in the Golgi
apparatus [1]. This gene is located in the chromosome 2
(2q12), and the 8382 bases mRNA encoding the isozyme
A (NCBI, NM_012214) contains 15 introns, 16 exons and
encodes a protein of 535-aminoacids (NCBI,
NP_036346). The MGAT4A  gene is well conserved as
demonstrate the 96% identity on the primary aminoacid
sequence shared between the MGAT4A and the bovine
GnT-IV glycosilases [1]. Transcripts of 9.7, 7.6, 5.1, 3.8,
and 2.4 kb have been detected by Northern-blot in several
human tissues and human derived cell lines; and the rela-
tive expression levels of these transcripts were similar
among the different tissues and cell lines tested, with
higher expression in spleen, thymus, peripheral blood
leukocytes, lymph node, prostate, pancreas, and small
intestine [1]. In the case of the cell lines tested, the promy-
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elocytic leukemia cell line HL-60 and the lymphoblastic
leukemia cell line MOLT-4 showed the highest expression
[1]. The human glycosylase IV is a type II membrane pro-
tein, similar to other known Golgi glycosyltransferases
[2]. MGAT4A has three known isoforms and may play a
role regulating the availability of serum glycoproteins,
oncogenesis, and cell differentiation [1,3].
Oligosaccharide antigens are commonly used as tumor
markers and many studies have shown these antigens can
modulate tumor cell adhesion, motility, and invasiveness
[3]. Recently the MGAT4A  was identified as a genetic
marker for pancreatic cancer in addition to its known role
in choriocarcinoma development [4]. It is remarkable
since reports of defects in protein glycosylation are
becoming increasingly associated with a range of human
diseases [2].
It has been shown that high counts of peripheral white
blood cells (WBC) are associated with insulin resistance
and type 2 diabetes (T2D) [5-7]. Concomitant to this
increment, polymorphonuclear and mononuclear cells
can be activated by advanced glycation end products [8],
oxidative stress [9,10], and cytokines in a state of hyperg-
lycemia, typical features of T2D [11]. On the other hand
lymphocytes have acquired significance like cell model to
study the expression of several biomarkers, since they
offer a convenient alternative to invasive methods of diag-
nosis aimed to measure the expression of several impor-
tant T2D associated genes [12,13].
The important role of MGAT4A function in the develop-
ment of T2D was shown in studies using engineered mice
lacking MgaT4a. These mice were phenotypically hyperg-
lycemic, hypoinsulinemic and had impaired glucose tol-
erance [14]. The role of MgaT4a on controlling the traffic
of GLUT2 in pancreatic β cells was described in these
mice, linking a high fat diet with the development of
experimental diabetes in mice [14].
As has been mentioned before, alterations in the expres-
sion of this gene have been implicated in the development
of several human diseases such as choriocarcinoma and
pancreatic cancer [3,4], showing that defective function of
this gene is of pathological consequence for the organism.
We hypothesized MGAT4A  gene expression might be
affected in individuals suffering of T2D. With this purpose
we determined the level of MGAT4A expression in white
cells of peripheral blood of well characterized T2D
patients and healthy subjects, and measure the half-life of
the transcript in a model lymphocyte T cell line.
Results
T2D phenotype biochemical tests and WBC counts
The clinical and biochemical profile of the subjects under
study are summarized in the Table 1. T2D subjects have an
average of seven years of evolution, and the average age of
the selected group of subjects in both categories are com-
parable, guaranteeing the healthy condition of controls.
In the T2D group, the biochemical values for glucose,
HDL and LDL parameters are in concordance with the
phenotype of the disease. The BMI for both groups indi-
cates overweight, what is a common feature in nowadays
Mexico City's inhabitants. The diastolic and systolic blood
pressures in both groups show absence of hypertension
and none of the participants had cardiovascular complica-
tions at the time of the study. Neither group of subjects
received anti-hypertensive drugs to control the blood
pressure. The blood cell count showed T2D exhibit an
increase number of WBC compared to the T2NB group (P
= 0.0001) (Table 1).
MGAT4A mRNA expression levels
We detected the presence on MGAT4A transcripts in WBC,
employing Real-Time PCR and primers designed to
Table 1: Clinical characteristics of the participants in the study
T2D T2NB P
n (male/female) 40 (20/20) 33 (17/16)
Age (years) 51.26 ± 7.77 51.19 ± 4.70 0.96
BMI (Kg/m2) 27.87 ± 3.80 26.80 ± 3.04 0.18
SBP (mm Hg) 124.61 ± 16.02 118.50 ± 8.27 0.05
DBP (mm Hg) 79.58 ± 10.29 76.09 ± 6.55 0.09
Glucose (mmol/l) 9.71 ± 4.04 4.91 ± 0.36 0.0001
Cholesterol (mmol/l) 5.64 ± 1.23 5.47 ± 0.88 0.50
HDL (mmol/l) 1.17 ± 0.26 1.24 ± 0.41 0.37
LDL (mmol/l) 3.60 ± 0.88 3.43 ± 1.54 0.55
Triglycerides (mmol/l) 2.54 ± 1.49 1.67 ± 0.61 0.002
WBC (cells/ml) 8.19 × 106 ± 6.64 × 102 5.90 × 106 ± 8.59 × 102 0.0001
Data are means ± SD; T2D, Type 2 Diabetes subjects; T2NB, healthy no T2D background unrelated subjects.BMC Genetics 2007, 8:73 http://www.biomedcentral.com/1471-2156/8/73
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amplify a 323 bp region the of MGAT4A transcript (Figure
1B). The MGAT4A mRNA expression levels quantified in
WBC (Figure 2) revealed a 4.2-fold increase in mRNA lev-
els in T2D subjects with respect to T2NB subjects (T2D
subjects 1.19 ± 0.21 vs. T2NB subjects, 0.25 ± 0.06, P =
0.002).
MGAT4A mRNA half-life determination
The MGAT4A mRNA half life was determined using Jurkat
lymphocyte T-cell line as a model under Actinomycin D
general RNA synthesis inhibition. The Figure 3 shows a
half-life of 2.04 h for MGAT4A  as measured by copy
number detection in Jurkat T cells (Kd = 0.339 h-1). The β-
actin mRNA half-life in the same cells was of 6.17 h (Kd =
0.112 h-1) as measured by detection of the 597 pb β-actin
fragment.
Discussion
In this work we measured the MGAT4A mRNA transcript
concentration present in WBC from T2D subjects and
healthy no T2D background unrelated subjects, as well as
measured the half-life on this transcript in the Jurkat T cell
line used as model. Our results shows that MGAT4A gene
expression in WBC from T2D patients exhibited higher
levels of transcripts concentration compared to the
healthy subjects (Figure 2). This result is remarkable since
in the mice model, the MGAT4A transcripts levels have
been reported low, while the animals are phenotipically
A) The gene structure for MGAT4A gene Figure 1
A) The gene structure for MGAT4A gene. The MGAT4A exons are shown as rectangles in the DNA and mRNA molecules; 
introns are indicated as a continuous line in DNA and break lines in the mRNA molecule. Primers GNTF and GNTR amplify a 
323 bp continuous portion of exons 2 and 3. Figure not to scale. Gene information, NCBI, NM_012214. B) 1% agarose gel frac-
tionation of the 323 bp PCR product amplified from cDNA made from healthy subjects (top) and T2D subjects (bottom). WM: 
100 bp molecular weight marker.
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hyperglycemic, hypoinsulinemic and had impaired glu-
cose tolerance [14,15]. One explanation to this result is
we measured the transcripts in WBC and not in pancreatic
β-cells being this difference due to differential tissue spe-
cific gene expression. However a more interesting plausi-
ble explanation is the higher level of MGAT4A  gene
expression exhibited by the T2D subjects, is a conse-
quence of a low pro-inflammatory state derived of chronic
hyperglycaemia, a common condition in T2D patients
[16-18]. Interestingly the WBC count was higher in the
T2D subjects compared to the healthy individuals, sug-
gesting that the increase in MGAT4A transcripts levels and
WBC count are related with the metabolic disorder
observed in T2D patients. In the development of T2D it is
emerging the knowledge of the existence of many genes
that are down or up-regulated during the development of
the disease as is demonstrated in animal models [12].
The  MGAT4A  transcript exhibits a half-life of 2.04 h,
measured by Real-Time PCR in the human Jurkat T cell
line used like model in this work (Figure 3); this half-life
classifies this mRNA in the so called protein modification
group of transcripts, with an average half-life of <5 h [19].
Thus we propose that an increase in MGAT4A transcripts
level and augmented WBC number in the bloodstream
contribute to a pro-inflammatory state and other meta-
bolic alterations observed in T2D patients. This explana-
tion is based on the observation that high levels of glucose
and triglycerides contributes to high stress environment
for the WBC, mainly lymphocytes [20]. This stress could
trigger the activation of this type of cells, increasing even
more the WBC count and the MGAT4A transcript level,
but only in subjects with a particular T2D genetic back-
ground. We hypothesize this condition does not occurs in
healthy people prior to the onset of any clinical manifes-
tation of the disease or prior to the hyperinsulinemia
mRNA half life determination Figure 3
mRNA half life determination. Cells were treated with 1 µM of Actinomycin D to block mRNA synthesis. mRNA decay was 
measured by detection of the 323 bp PCR product in Jurkat cells A) β-actin mRNA decay was measured by detection of 587 bp 
in the same cells B) The values represent the mean ± SE of (empty squares) or β-actin (filled squares) copy number per µg of 
total RNA from three independent experiments made by duplicate.
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MGAT4A mRNA expression in the phenotypic groups Figure 2
MGAT4A mRNA expression in the phenotypic groups. Indi-
viduals in each phenotypic category were grouped according 
to the clinic and biochemical parameters as T2D, type 2 Dia-
betes subjects and T2NB, healthy no T2D background sub-
jects. mRNA levels were quantified by Real-Time PCR and 
normalized to mRNA levels of β-actin. Results are expressed 
as the means ± SE. ANOVA P values are shown.
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present in obese individuals or T2D patients with recent
diagnosis.
Conclusion
We report a high expression of MGAT4A mRNA in WBC
of T2D patients; and we consider that glycosylase IVA
involved in WBC proliferation and activation associated
with the pro-inflammatory condition found in most cases
of T2D patients, is one of the several gene products with
an important role in the pathogenesis events triggering
diabetes. We also show white blood cells provide a sample
useful to measure the expression of these genes, which
permits to acquire data to infer about the pro-inflamma-
tory condition of the individuals in relation with diabetes.
We also found that the MGAT4A mRNA belongs to the
protein modification group of transcripts, with an average
half-life of less than 5 h.
Methods
Subjects Profile
A population-based register of individuals belonging to
low and medium economic ranks living in Mexico City
were selected from a T2D cohort. The case-control sample
consisted of 73 individuals divided in two phenotypic cat-
egories: 40 patients diagnosed with T2D within the last 7
years and 33 healthy unrelated subjects without T2D
background obtained from the Blood Bank at Centro
Medico Siglo XXI, IMSS in Mexico City. Diagnosis of T2D
was established according to the American Diabetes Asso-
ciation criteria. The study protocol was approved by the
IMSS Ethics Committee and informed consent was
obtained from all participants, in accordance with the
Helsinki Declaration revised in 2000. Patients with active
infections within the last two months or surgery within
the last three months previous to the test; with affections
as cancer; T1D, cardiopathy; or with any pharmacological
treatment (with exception of T2D) were excluded from
the study.
Biochemical studies
Participants were scheduled for clinical laboratory evalua-
tion following a 12 hour overnight fasting, and were
required to collect urine in the 24 h prior to the clinic visit.
Blood samples were taken to assess levels of fasting glu-
cose, total cholesterol, triglycerides and high and low den-
sity cholesterol levels (HDL, LDL). All the participants
were interviewed by a physician, and weight and height
were measured to calculate body mass index (BMI = kg/
m2). Systolic and diastolic blood pressure measurements
were made using a mercurial sphygmomanometer
(Hitachi) from both arms and the average of two measure-
ments was obtained. Biochemical measurements were
assayed for all subjects using a ILab 350 Clinical chemistry
System (Instrumentation laboratory IL). LDL-cholesterol
concentrations were derived from lipid values according
to the Friedewald formula [21].
Cell culture
The Jurkat T cell line was cultured in 75 ml bottles with 20
ml of RPMI-1640 medium (Sigma) supplemented with 2
mM glutamine, 1.5 g/L NaHCO3, glucose 25 mM, 0.1 mg/
ml gentamicin and 10% heat inactivated Bovine Calf
Serum. Fresh medium was added according to standard
tissue culture techniques. Viability was verified with
Trypan Blue (Sigma).
White blood cells count
The total red blood cell count; total white blood cell count
and the fraction for platelets was made using an auto-
mated blood cell counter (Sysmex K-4500, TOA Medicals
Electronics), using a 4 ml sample of peripheral blood
from each individual.
RNA extraction and RT-PCR
Total RNA was purified directly from 1.0 × 107 WBC and
from 2.2 × 106 Jurkat cells using a QIAamp RNA kit (Qia-
gen) following the manufacturer's instructions. Integrity
of DNase I treated RNA was verified by electrophoresis in
1.0% agarose gel stained with ethidium bromide and its
concentration was measured by spectrophotometry at
260/280 nm. cDNA was synthesized using 1 µg of total
RNA by RT-PCR with Super Script-II Reverse transcription
enzyme (Invitrogen) and random primers (Invitrogen) in
a GeneAmp PCR System 2700 (Applied Biosystems).
Cloning of MGAT4A and β-actin gene fragments
A 323 bp region of the MGAT4A  gene (NCBI,
NM_012214) was amplified from cDNA (Figure 1A)
using the primers GNTF 5'-TTG GCC TAG AGC CAG GAG
TA-3' and GNTR 5'-ACA CGC TTG AAC TGT TGC AC-3',
and a 597 bp region of the β-actin gene (NCBI,
NM_001101) was amplified from cDNA using the prim-
ers BAF 5'-CCA AGG CCA ACC GCG AGA AGA TGA C-3'
and BAR 5'-AGG GTA CAT GGT GGT GCC GCC AGA C-
3'. PCR products were cloned into pCR-Blunt II TOPO
(Invitrogen) to generate plasmids pTOPO-GNT323 and
pTOPO-BA597, respectively. The plasmids were purified
using the midi plasmid kit (Qiagen) according to the
manufacturer's protocol and quantified by 260/280 nm
spectrophotometry. Cloned fragments were sequenced
using Big Dye terminator reagent v3.1 (Applied Biosys-
tems) using primers Sec-For 5'-CAG GAA ACA GCT ATG
A-3' and Sec-Rev 5'-CTG GCC GTC GTT TTA-3'. Analysis
of sequencing reactions was made in an ABI Prism 310
(Applied Biosystems).
Quantitation of MGAT4A mRNA using Real-Time PCR
Detection of the MGAT4A was performed by Real-Time-
PCR using primers GNTF and GNTR to amplify a 323 bpBMC Genetics 2007, 8:73 http://www.biomedcentral.com/1471-2156/8/73
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product and BAF and BAR primers to amplify a 597 bp β-
actin product. Serial ten-fold dilutions ranging from 104
to 108 molecules for each plasmid were prepared. Each
standard curve was constructed with averaged data of
three independent measurements made by triplicate.
These curves were used to estimate the initial transcript
copy number for MGAT4A and β-actin in cDNA samples
prepared from total RNA. Real-Time PCR reactions were
performed in a 10 µl of reaction volume using 1/10 of the
20 µl cDNA reaction as initial template. The DNA Fast
Start SYBR-green Kit (Roche) and the Light Cycler 2.0
(Roche) were employed to perform the amplifications of
MGAT4A and β-actin target, according to manufacturer's
instructions. The Light Cycler software version 4.0 was
used to analyze the fluorescence and number of cycles of
each reaction. One point MGAT4A mRNA concentration
was made in white cells from T2D and T2NB subjects. The
transcript concentration was the average of triplicate
determinations and was expressed as a normalized value
to the β-actin mRNA levels for each individual.
Determination of mRNA half-life
Detection of a 323 bp MGAT4A and a 587 bp β-actin RT-
PCR products in the same cells were used to estimate
mRNA half-lives in Jurkat T cell line. The cell cultures were
treated with 1 µM Actinomycin D (Sigma-Aldrich, USA)
to inhibit the transcription. Twenty four hours before
treatment the cells were transferred from the 75 mL tissue
bottle to 10 cm culture dishes in aliquots of 2.2 × 106 cells.
Under these conditions we performed three independent
experiments where cells were collected every 2 h and total
RNA was isolated as described before.
Statistical Analysis
The anthropometric and biochemical measurements are
expressed as means ± SD, whereas gene expression meas-
urements are expressed as means ± SE. The analysis of the
data were made by ANOVA and tested for differences
between groups using the Kruskal-Wallis analysis. P ≤ val-
ues 0.05 were considered to be significant. Statistical oper-
ations were performed using the Stat View v4.57 (SAS
Institute Inc., USA) and Prism 4 v4.02 (GraphPad Soft-
ware, USA).
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